Patents by Inventor Irina Cipora Jacobson

Irina Cipora Jacobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6281352
    Abstract: This invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor. The present invention also relates to pharmaceutical compositions comprising such compounds and to methods of using these compounds for the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: August 28, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Chu-Bio Xue, Carl P. Decicco, Robert J. Cherney, Elizabeth Arner, William F. DeGrado, Jingwu Duan, Xiaohua He, Irina Cipora Jacobson, Ronald L. Magolda, David Nelson
  • Patent number: 6110910
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: August 29, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • Patent number: 5874441
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: February 23, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt
  • Patent number: 5703092
    Abstract: The present invention provides novel hydroxamic acids and carbocyclic acids and derivatives thereof and to pharmaceutical compositions and methods of use of these novel compounds for the inhibition of matrixmetalloproteinases, such as stromelysin and other matrix metalloproteinases, and also inhibit the production of tumor necrosis factor (TNF), and are therefore useful for the treatment of arthritis and other related inflammatory diseases.
    Type: Grant
    Filed: April 16, 1996
    Date of Patent: December 30, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Chu-Biao Xue, William F. DeGrado, Carl Peter DeCicco, Irina Cipora Jacobson
  • Patent number: 5691381
    Abstract: The present invention provides novel hydroxamic acids and carbocyclic acids and derivatives thereof and to pharmaceutical compositions and methods of use of these novel compounds for the inhibition of matrix metalloproteinases, such as stromelysin, and inhibit the production of tumor necrosis factor alpha, and for the treatment of arthritis and other related inflammatory diseases.
    Type: Grant
    Filed: April 16, 1996
    Date of Patent: November 25, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Irina Cipora Jacobson, Carl Peter Decicco, Robert Joseph Cherney
  • Patent number: 5639759
    Abstract: This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumatoid arthritis, and cancer in a mammal.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: June 17, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Ronald Louis Magolda, William John Pitts, Irina Cipora Jacobson, Carl Henry Behrens, Michael James Orwat, Douglas Guy Batt